Modulating the cellular uptake of platinum drugs with glycopolymers

Dag, A; Callari, M; Lu, H; Stenzel, MH

Modulating the cellular uptake of platinum drugs with glycopolymers

Dag, A Callari, M Lu, H

Stenzel, MH

Permalink

Publisher:: ROYAL SOC CHEMISTRY
Publication Type:: Journal Article
Citation:: Polym. Chem., 2016, 7, (5), pp. 1031-1036
Issue Date:: 2016

Closed Access

	Filename	Description	Size
	c5py01579k.pdf	Published version	1.16 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Dag, A
dc.contributor.author	Callari, M
dc.contributor.author	Lu, H https://orcid.org/0000-0001-6932-1900
dc.contributor.author	Stenzel, MH
dc.date.accessioned	2022-08-21T21:48:19Z
dc.date.available	2022-08-21T21:48:19Z
dc.date.issued	2016
dc.identifier.citation	Polym. Chem., 2016, 7, (5), pp. 1031-1036
dc.identifier.issn	1759-9954
dc.identifier.issn	1759-9962
dc.identifier.uri	http://hdl.handle.net/10453/160620
dc.description.abstract	The therapeutic potency of platinum-based anticancer drugs can be substantially improved through the use of polymeric nanocarrier systems to target cancer cells efficiently. We synthesized a series of glyco-block copolymers with three different sugars able to self-assemble into nanoparticles when conjugated with 1,2-diamino-cyclopentane platinum(ii) (DACP-Pt). The polymers are based on (2-(d-glucosyloxy)ethyl methacrylate (glucose; GlcMA), 2-(d-galactosyloxy)ethyl methacrylate (galactose; GalMA), 1-O-methacryloyl-β-d-fructopyranose (fructose; FrucMA1), and 3-O-methacryloyl-β-d-fructopyranose (fructose; FrucMA3)). They are all readily taken up intracellularly by the breast cancer cell lines MCF-7 and MDA-MB-231 and the ovarian cancer cell line A2780. All cell lines expressed a high preference for the fructose coated nanoparticles. The nanocarriers were themselves nontoxic, but exhibited high cytotoxicity and increased efficacy when conjugated with the DACP-Pt drug.
dc.language	English
dc.publisher	ROYAL SOC CHEMISTRY
dc.relation.ispartof	Polym. Chem.
dc.relation.isbasedon	10.1039/c5py01579k
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0303 Macromolecular and Materials Chemistry, 0307 Theoretical and Computational Chemistry
dc.title	Modulating the cellular uptake of platinum drugs with glycopolymers
dc.type	Journal Article
utslib.citation.volume	7
utslib.for	0303 Macromolecular and Materials Chemistry
utslib.for	0307 Theoretical and Computational Chemistry
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	/University of Technology Sydney/Strength - IBMD - Initiative for Biomedical Devices
utslib.copyright.status	closed_access	*
dc.date.updated	2022-08-21T21:48:18Z
pubs.issue	5
pubs.publication-status	Published
pubs.volume	7
utslib.citation.issue	5

Abstract:

The therapeutic potency of platinum-based anticancer drugs can be substantially improved through the use of polymeric nanocarrier systems to target cancer cells efficiently. We synthesized a series of glyco-block copolymers with three different sugars able to self-assemble into nanoparticles when conjugated with 1,2-diamino-cyclopentane platinum(ii) (DACP-Pt). The polymers are based on (2-(d-glucosyloxy)ethyl methacrylate (glucose; GlcMA), 2-(d-galactosyloxy)ethyl methacrylate (galactose; GalMA), 1-O-methacryloyl-β-d-fructopyranose (fructose; FrucMA1), and 3-O-methacryloyl-β-d-fructopyranose (fructose; FrucMA3)). They are all readily taken up intracellularly by the breast cancer cell lines MCF-7 and MDA-MB-231 and the ovarian cancer cell line A2780. All cell lines expressed a high preference for the fructose coated nanoparticles. The nanocarriers were themselves nontoxic, but exhibited high cytotoxicity and increased efficacy when conjugated with the DACP-Pt drug.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/160620